Glucagon-like peptide-1, glucose homeostasis and diabetes.
Research output: Contribution to journal › Journal article › peer-review
Incretins, enhancers of insulin secretion, are essential for glucose tolerance, and a reduction in their function might contribute to poor beta-cell function in patients with type-2 diabetes mellitus. However, at supraphysiological doses, the incretin glucagon-like peptide-1 (GLP-1) protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying and food intake, leading to weight loss. GLP-1 mimetics, which are stable-peptide-based activators of the GLP-1 receptor, and incretin enhancers, which inhibit the incretin-degrading enzyme dipeptidyl peptidase-4, have emerged as therapies for type-2 diabetes and have recently reached the market. The pathophysiological basis the clinical use of these therapeutics is reviewed here.
Original language | English |
---|---|
Journal | Trends in Molecular Medicine |
Volume | 14 |
Issue number | 4 |
Pages (from-to) | 161-8 |
Number of pages | 8 |
ISSN | 1471-4914 |
DOIs | |
Publication status | Published - 2008 |
Bibliographical note
Keywords: Diabetes Mellitus; Glucagon-Like Peptide 1; Glucose; Homeostasis; Humans
ID: 8416785